Antileishmanial and antitrypanosomal drug identification
by Croft SL, Chatelain E, Barrett MP.
Emerging Topics in Life Sciences, December 2017
Phenotypic screening approaches for Chagas disease drug discovery
by Chatelain E, Ioset JR.
Expert Opinion on Drug Discovery, December 2017
Regulatory Affairs Professionals Society [8 December, 2017]
“Have PRVs incentivized new rare or neglected disease research? Experts discuss”
First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease
by Ramírez JC, Parrado R, Sulleiro E, de la Barra A, Rodríguez M, Villarroel S, Irazu L, Alonso-Vega C, Alves F, Curto MA, García L, Ortiz L, Torrico F, Gascón J, Flevaud L, Molina I, Ribeiro I, Schijman AG.
PLOS ONE, November 2017
FLAP XXIV Latin American Parasitology Congress
December 10-14, 2017
Santiago de Chile, Chile
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America presented on Chagas disease at the event.
El Tiempo [26 November, 2017]
“La silenciosa batalla contra la enfermedad de Chagas” – “The silent battle against Chagas disease”
GHIT R&D Forum
December 8, 2017
Tokyo, Japan
DNDi presented at the event on the NTD Drug Discovery Booster, Chagas disease, and mycetoma.
DNDi reçoit le Prix 2017 de l’Innovation à Genève pour récompenser son action en faveur des populations les plus négligées
A l’occasion de l’Evénement économique 2017 du 9 novembre dernier, la Chambre de commerce, d’industrie et des services de Genève (CCIG), le Département de la sécurité et de l’économie (DSE) et l’Office de Promotion des Industries et des Technologies (OPI) ont décerné le Prix 2017 de l’innovation à l’initiative Médicaments contre les Maladies Négligées (DNDi).
DNDi awarded the Innovation Prize 2017 in Geneva for working to help the most neglected
As part of the ‘Evénement économique 2017’ that took place on November 9, the Geneva Chamber of Commerce, Industry and Services (CCIG), the Department of Security and Economy (DSE) and the Office for the Promotion of Industries and Technologies (OPI) awarded the Innovation Prize 2017 to the Drugs for Neglected Diseases initiative (DNDi).
NPR [10 September, 2017]
“Drug for ‘neglected’ Chagas disease gains FDA approval amid price worries”
Slate [7 September, 2017]
“A new strategy to undermine big pharma’s price gouging actually worked”
ISNTD Blog [5 September, 2017]
“Infectious thoughts interviews: Dr. Carolina Batista”
La Nación [1 September, 2017]
“Chagas: EE.UU. aprobó un fármaco argentino” – “Chagas: US approves an Argentine drug”
Click here to read the article
FDA aprova o medicamento benznidazol para tratamento da doença de Chagas em crianças
[Washington, Buenos Aires, Madrid, Genebra – 31 de agosto de 2017]
No último dia 29 de agosto, a FDA, agência do governo americano para vigilância sanitária de alimentos e medicamentos, aprovou a solicitação de registro do medicamento benznidazol, feito pelo Chemo Group. Trata-se do primeiro medicamento aprovado pela FDA para o tratamento da doença de Chagas.
[English] [Español]
Estados Unidos aprueba el benznidazol para el tratamiento de niños con la enfermedad de Chagas
[Washington D.C.,Buenos Aires/Madrid/Ginebra – 31 de agosto de 2017]
El 29 de agosto, la Administración de Alimentos y Fármacos de Estados Unidos (FDA, por sus siglas en inglés) aprobó la solicitud de nuevo fármaco para el benznidazol del Grupo Chemo. Se trata del primer medicamento aprobado por la FDA para tratar la enfermedad de Chagas.
[English] [Português]
U.S. FDA approves Chemo Group’s benznidazole to treat children with Chagas disease
[Washington DC, Geneva – 31 August 2017]
On August 29th, the U.S. Food and Drug Administration (FDA) approved Chemo Research’s New Drug Application (NDA) for benznidazole. This is the first drug ever approved by the FDA to treat Chagas disease.
[Español] [Português]